Damien P.
- Country
- France
- Department
- Oncology
Research Overview
- Phase I Study of XL092 Monotherapy and Combination Therapy in Advanced Solid Tumors: ccRCC, nccRCC, HR+ BC, mCRPC, and CRC
- Phase 3 Study of Vepugratinib and Combination Therapy in Adults with Untreated FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
- Phase 3 Randomized Study of Belzutifan Plus Zanzalintinib Versus Belzutifan Plus Placebo in Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy
Data & Insights
Has run more than one trial at 204 of 403 partner sites.
Specializations
Bladder Cancer Research
This investigator specializes in both muscle-invasive bladder cancer (MIBC) and non-muscle invasive bladder cancer (NMIBC) treatments, with particular attention to innovative therapeutic approaches.
- High-risk NMIBC treatment protocols
- Neoadjuvant therapy for MIBC
- FGFR3-altered urothelial carcinoma
The investigator explores targeted therapies and immunotherapy combinations for bladder cancer treatment.
Renal Cell Carcinoma Studies
Focuses on advanced treatments for metastatic renal cell carcinoma (mRCC), including both clear cell and non-clear cell variants.
- First-line treatment strategies
- Papillary renal cell carcinoma
- Adjuvant therapy approaches
Investigates novel combination therapies involving immune checkpoint inhibitors and targeted agents.
Advanced Therapeutic Approaches
Specializes in targeted therapy development and immunotherapy combinations for urological cancers.
- Maintenance therapy strategies
- Novel drug combinations
- Biomarker-driven treatments
Explores innovative treatment modalities for patients with advanced urological malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.